Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I fucking have a high fever and I'm still confused!
damn
LOL
I did not think to buy it back but at 1.70 it is a gift!
Thanks CBIO
Yes!
65 milion
Brokerage believes Sunosi has potential to become a mainstay as first-line non-generic therapeutic in these indications; assumes peak market penetration of 14%
Cantor Fitzgerald raises PT for drug developer Axsome Therapeutics (AXSM.O) to $64 from $47 on growth potential of its newly acquired drug Sunosi
STRONG BUY
https://fintel.io/sst/us/axsm
from next week approval at any time!
Bull trap
the temptation is great but I'm not selling!
ObsEva Announces UK MHRA Marketing Authorization for Yselty® (linzagolix)
https://fintel.io/so/us/epix
I am tempted to add, but I am waiting maybe they charge me $ 3 or even $ 2
Go as you go, how can you not keep them?
Insider Ownership 21.93%
Institutional Shares (Long) - 96.63% (ex 13D/G)
MC $120M
At March 31, 2022, the Company had available cash reserves and short-term investments of $181.0 million reflecting the gross proceeds of the February 2021 financing of approximately $150.0 million and July 2020 financing of $48.9 million, less operating expenses in the intervening period. The Company's cash position is expected to be sufficient to fund current and planned operations through 2024.
what do you think of the change in communication?
With McNully we would have known in the second half of 2023
https://pdfpiw.uspto.gov/.piw?PageNum=14&docid=11369353&IDKey=8D79D6161BC4&HomeUrl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO2%2526Sect2%3DHITOFF%2526p%3D1%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-bool.html%2526r%3D1%2526f%3DG%2526l%3D50%2526co1%3DAND%2526d%3DPTXT%2526s1%3D%252522titan%252Bmedical%252522%2526OS%3D%252522titan%252Bmedical%252522%2526RS%3D%252522titan%252Bmedical%252522
https://pdfpiw.uspto.gov/.piw?PageNum=16&docid=11369353&IDKey=8D79D6161BC4&HomeUrl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO2%2526Sect2%3DHITOFF%2526p%3D1%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-bool.html%2526r%3D1%2526f%3DG%2526l%3D50%2526co1%3DAND%2526d%3DPTXT%2526s1%3D%252522titan%252Bmedical%252522%2526OS%3D%252522titan%252Bmedical%252522%2526RS%3D%252522titan%252Bmedical%252522
https://pdfpiw.uspto.gov/.piw?PageNum=20&docid=11369353&IDKey=8D79D6161BC4&HomeUrl=http%3A%2F%2Fpatft.uspto.gov%2Fnetacgi%2Fnph-Parser%3FSect1%3DPTO2%2526Sect2%3DHITOFF%2526p%3D1%2526u%3D%25252Fnetahtml%25252FPTO%25252Fsearch-bool.html%2526r%3D1%2526f%3DG%2526l%3D50%2526co1%3DAND%2526d%3DPTXT%2526s1%3D%252522titan%252Bmedical%252522%2526OS%3D%252522titan%252Bmedical%252522%2526RS%3D%252522titan%252Bmedical%252522
FDA proposed labeling for depression drug
Do you have doubts that it will be approved?
Those who sell do not understand what it means!
$ 200
cover up soon or it will be bitter cocks!
Insider Ownership 38.12%
Institutional Shares 51.92% (ex 13D/G)
https://fintel.io/sst/us/axsm
BHUAHAHAHAHHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAHAH
and today to pump a little more, here:
https://ih.advfn.com/stock-market/NASDAQ/axsome-therapeutics-AXSM/stock-news/88423608/axsome-therapeutics-to-host-sunosi-investor-updat
ESSA PHARMA INC
EPI-7386 WAS SAFE AND WELL-TOLERATED AT ALL DOSE LEVELS
EPI-7386 SCHEDULES TESTED WITH PLASMA TARGET CONCENTRATIONS ACHIEVED AND CLINICALLY IMPORTANT EFFICACY SIGNALS
ESSA PHARMA INC - EXPECTS TO INITIATE PHASE 1B MONOTHERAPY EXPANSION STUDY IN Q3 2022
We are pleased with the progress in advancing our novel prostate cancer candidate EPI-7386 as a monotherapy in patients with advanced mCRPC.
We continue to be excited by our combination trials evaluating EPI-7386 with the four leading, commercially available antiandrogens in earlier line patient populations
I hope some huge portfolios get excited too...
I would like to take more!
We are full of depressed people who need to be helped!
Life if you think about it is a stupid thing but if you don't think about it it can be wonderful!
BOOM
https://patft.uspto.gov/netacgi/nph-Parser?Sect1=PTO2&Sect2=HITOFF&p=1&u=%2Fnetahtml%2FPTO%2Fsearch-bool.html&r=1&f=G&l=50&co1=AND&d=PTXT&s1=%22titan+medical%22&OS=%22titan+medical%22&RS=%22titan+medical%22
Articulated tool positioner and system employing same
Who sold?
Me no
the study says August but if they say they will give advances in the second quarter ... here we are!
$ 1,77
took a handful at 34.77
I can't resist!
sorry wrong board
strange volume
how much patience here!
Gimme gimme gimme some green!
Monotherapy
Present clinical update on phase 1 trial. 1H 2022
Establish the recommended phase 2 dose (RP2D). 1H 2022
Initiate the expansion portion of phase 1 trial. 1H 2022
Combination
Initiate phase 1 portion of EPI-7386 combination trials with all partners. 1H 2022
https://clinicaltrials.gov/ct2/show/NCT05075577?cond=EPI-7386&draw=2&rank=1
https://clinicaltrials.gov/ct2/show/NCT04421222?cond=EPI-7386&draw=2&rank=2
https://clinicaltrials.gov/ct2/show/NCT05295927?cond=EPI-7386&draw=2&rank=3
I thought about your question but I can't answer it!
I can't wait for them to say they have closed development!
They are currently at work, who knows what?
A dozen or more new engineers have joined since November.
I think they are working on the software mainly!
So I don't know how to evaluate!
Even if I were MDT I would like to see the toy before closing!
dreaming.... when the toy is ready then maybe even 7
after all it is a positive day, with news like this it could have done even -50%
instead for now only -0.5%.
at the moment
maybe it's because it's Friday 17th
Uterine fibroids are the most common benign pelvic tumors in women. Because many UFs are asymptomatic, estimating prevalence is difficult. 1 In a recent systematic review, prevalence estimates range from 4.5 to 68.6%, depending on study population and methodology, 2 with prevalence increasing with age until menopause, then declining. 1 This prevalence is higher than other conditions in women such as hypertension, 3 breast cancer, 4 or ovarian cancer. 5 There are marked differences by race in both prevalence and incidence ( Fig. 1 ), with age-specific incidence and prevalence of UF higher in black women at all ages. 1 2 Using ultrasound screening, the estimated cumulative incidence rate of UF by the age of 50 is significantly higher in black women (80%) compared with white women (nearly 70%).
a booger!
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6193285/
I invested in the pu..y but it does not pay, see OBSV!
I fear some sexist conspiracy
I hope the d..k pays more! So Epix!
let's wait